Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607485 | 0.89 | TSHR (0.33) | TSHR | |
| SCHEMBL17607754 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL17135311 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL59580 | 0.83 | — | — | |
| SCHEMBL5985356 | 0.82 | — | — | |
| SCHEMBL17607425 | 0.82 | — | — | |
| SCHEMBL7566789 | 0.81 | LMNA (0.46) | ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL4654163 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL20400802 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL4279899 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999838-B2 | Resin additive composition, thermoplastic resin composition, and molded article thereof | ADEKA CORPORATION (JP) | 2024-06-04 | — | — | US | disclosed |
| EP-4372042-A2 | RESIN ADDITIVE COMPOSITION, THERMOPLASTIC RESIN COMPOSITION, AND MOLDED ARTICLE THEREOF | Adeka Corporation (JP) | 2024-05-22 | — | — | EP | disclosed |
| EP-3424993-B1 | RESIN ADDITIVE COMPOSITION, THERMOPLASTIC RESIN COMPOSITION, AND MOLDED ARTICLE THEREOF | ADEKA CORP (JP) | 2024-05-01 | — | — | EP | disclosed |
| EP-4350057-A1 | THERMOPLASTIC RESIN COMPOSITION, METHOD FOR PRODUCING SHAPED BODY, SHAPED BODY AND USE OF RESIN MATERIAL | ADEKA CORPORATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| US-20230073126-A1 | RESIN ADDITIVE COMPOSITION, THERMOPLASTIC RESIN COMPOSITION, AND MOLDED ARTICLE THEREOF | ADEKA CORPORATION (JP) | 2023-03-09 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115397467-A | Therapeutic agent for tauopathy | 住友制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| CN-106795431-A | Heat stabilizer composition and use its compound resin composition | 株式会社ADEKA | 2017-05-31 | — | — | CN | disclosed |
| US-9644315-B2 | Method for inkjet textile printing | MATSUI SHIKISO CHEMICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160251497-A1 | METHOD FOR PRODUCING STABILIZED POLYMER | ADEKA CORPORATION (JP) | 2016-09-01 | — | — | US | disclosed |
| EP-3061788-A1 | METHOD FOR PRODUCING STABILIZED POLYMER | Adeka Corporation (JP) | 2016-08-31 | — | — | EP | disclosed |
| CN-105683278-A | Method for producing stabilized polymer | 株式会社ADEKA | 2016-06-15 | — | — | CN | disclosed |
| US-20140186533-A1 | METHOD FOR INKJET TEXTILE PRINTING | MATSUI SHIKISO CHEMICAL CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-6034211-A | β-sheet nucleating peptidomimetics | KELLY JEFFERY W (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1998027972-A9 | ANTI-AMYLOIDOGENIC AGENTS | — | 1998-11-05 | — | — | WO | disclosed |
| WO-1998027972-A2 | ANTI-AMYLOIDOGENIC AGENTS | TEXAS A & M UNIVERSITY (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1997046547-A1 | β-SHEET NUCLEATING PEPTIDOMIMETICS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | ALDH1A1 4081/4885TDP1 614/4885TSHR 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.